3:59 PM
 | 
Nov 21, 2016
 |  BC Extra  |  Clinical News

FDA lifts partial hold on Aduro's candidates

Aduro Biotech Inc. (NASDAQ:ADRO) said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes-based immunotherapy construct (LADD) platform. The studies may resume enrollment. Patients in the trials had continued to receive treatment.

The agency placed...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >